New England Journal of Medicine· 2012Q1· Clinical trial
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
- 2,353citations
- Q1SCImago
- 2012year
Short summary
A fixed-dose oral rivaroxaban regimen proved noninferior to standard anticoagulant therapy for treating symptomatic pulmonary embolism, with a significantly lower rate of major bleeding.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Internal Medicine
Internal MedicineMedicine